[HTML][HTML] Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma

MY Kim, JY Shin, JO Kim, KH Son, YS Kim, CK Jung… - BMC cancer, 2020 - Springer
Background Hypoxic tumors are known to be highly resistant to radiotherapy and cause
poor prognosis in non-small cell lung cancer (NSCLC) patients. CKD-516, a novel vascular …

Synergistic antitumor effect of taxanes and CDK4/6 inhibitor in lung cancer cells and mice harboring KRAS mutations

KH Son, MY Kim, JY Shin, JO Kim… - Anticancer Research, 2021 - ar.iiarjournals.org
Background/Aim: LY2835219 (LY), a novel CDK4/6 inhibitor, prevents cell proliferation
through G1 arrest. Docetaxel (DTX) and paclitaxel (PTX) are cytotoxic drugs targeting tubulin-…

The clinical characteristics of RET rearranged lung adenocarcinoma patients.

JO Kim, J Lee, JY Shin, MY Kim, KH Son, CK Jung… - 2015 - ascopubs.org
e18528 Background: KIF5B-RET fusion genes are formed when part of the RET gene fuses
with part of the KIF5B gene. This fusion gene induces the proliferation and differentiation of …

Detection of RET (rearranged during transfection) variants and their downstream signal molecules in RET rearranged lung adenocarcinoma patients

JO Kim, JY Shin, MY Kim, KH Son, CK Jung, TJ Kim… - Surgical Oncology, 2018 - Elsevier
Background We screened resected tumor tissues from patients with lung cancer for EGFR
mutations, ALK rearrangements, and rearranged during transfection (RET) gene variants (…

EGFR mutations in tumor tissue and blood collected from lung cancer patients by Insight Onco NGS technique.

JH Kang, JY Shin, JO Kim, MY Kim, KH Son, HW Lee… - 2016 - ascopubs.org
e20017 Background: Activating or resistant somatic mutations (19 Del, L858R, T790M)
occurring in the specific sites of EGFR gene are the powerful predictive biomarker for EGFR …

Synergistic effect of combined cdk4/6 inhibitor with docetaxel in lung cancer cell lines harboring KRAS mutations

KH Son, JY Shin, JO Kim, JH Kang - Cancer Research, 2016 - AACR
Background & Purpose LY2835219(LY), a novel CDK4/6 inhibitor, inhibits phosphorylation
of RB and E2F activation, thereby arresting the cell cycle in the G1 phase and suppressing …

KIF5B-RET fusion gene may induce EMT via the regulation of two transcription factors, FOXA2 and STAT5A

MY Kim, JY Shin, JO Kim, KH Son, JH Kang - Cancer Research, 2016 - AACR
Background & Purpose In recent, KIF5B-RET gene rearrangement has been discovered as
a driver oncogene in non-small cell lung cancers. This fusion gene was demonstrated to be …

Coexistence of rearranged during transfection (RET) variants and activating EGFR mutations with their molecular implications in lung adenocarcinomas.

JO Kim, JY Shin, MY Kim, KH Son, CK Jung, TJ Kim… - 2017 - ascopubs.org
e20610 Background: RET rearrangements have been identified in 1-2% of lung adenocarcinomas.
The most common fusion is the KIF5B-RET, the function and roles of the RET fusion …

Tumorigenic activity of a novel KIF5B-RET fusion gene

JY Shin, MY Kim, KH Son, JO Kim, JH Kang - Cancer Research, 2015 - AACR
The KIF5B-RET gene is a novel fusion gene resulting from pericentric inversion between
the kinesin family member 5B (KIF5B) and the rearranged during transfection (RET) gene, …

The upregulation of FOXA2 transcription factor in RET rearranged lung adenocarcinoma.

JO Kim, JY Shin, MY Kim, KH Son, CK Jung, SJ Bae… - 2016 - ascopubs.org
e20014 Background: KIF5B-RET gene rearrangement occurs in about 1% of lung adenocarcinomas.
In recent, the targeted agents to inhibit RET phosphorylation have been examined …